Skip to main content
Back to all tickers

Cue Biopharma, Inc. (CUE) stock forecast & analysis

4.50

NasdaqCM · USDDelayed by 15 minutes

Down: -0.26, -5.5%

4.30Down: -0.20, -4.4%

1 analysis

Use Arrow keys to explore price history; Home and End jump to the oldest and newest points
Price history for CUE.US from 10-21 13:30 to 11-20 00:50 with 1 analysis run marked; public runs are shown as stance-colored dots (Bullish, Bearish, or Neutral) and gated runs as a lock icon (sign in to read). Each marker is a link to sign in.BullishBearishNeutralLocked · sign in to read

Latest analysis: · verdict locked

Open
4.55
Previous close
4.76
Day range
3.85 – 5.16
52-week range
2.83 – 45.50
Volume (shares)
2.06M
Net assets
Not available
Expense ratio
Not available
Shares outstanding
8.36M
P/E ratio
Not available
Dividend yield
0.00%
Beta
Not available
Market cap
37.62M
Market Scanner’s AI analysis of Cue Biopharma, Inc. (CUE), updated November 2026: Cue Biopharma's recent analyses focused on a dramatic price collapse and the lack of substantive news flow.

This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Cue Biopharma, Inc. (CUE) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.

Summary

Cue Biopharma's recent analyses focused on a dramatic price collapse and the lack of substantive news flow.

Recent analyses for Cue Biopharma (CUE) covered a significant price decline from the $28–38 range to a recent close of $4.76, falling through major technical levels. The stock experienced a sharp rebound on high volume, but this was not seen as an established base. The news flow was limited, with only one relevant company-specific event being the Q3 2026 results announcement, though details on financials or pipeline milestones were not available.

CUE news & sentiment

News flow for Cue Biopharma was sparse, with limited company-specific events and a lack of detailed financial information. Social media discussion was not covered in the provided notes.

CUE technical picture

CUE experienced a sharp price collapse, falling through all major technical levels and trading significantly below its 50-day and 200-day SMAs. A recent rebound occurred on high volume, but this was not characterized as an established base.

Fundamentals

The analysis covered Cue Biopharma's market capitalization and share price relative to its 52-week range and moving averages, noting a significant decline from its highs. No information was provided on revenue, margins, cash flow, or capital intensity.

Factors discussed — upside

  • Sharp rebound on high volume from a one-day low.

Factors discussed — risks

  • Price collapse from the $28–38 range to $4.76.
  • Stock has fallen through every major technical level.
  • Price is significantly below 50-day and 200-day SMAs.
  • Lack of substantive news flow and financial details from Q3 results.
  • Price action
  • Technical levels
  • News flow
  • Financials

Summary updated .

CUE technical indicators

Common technical indicators for CUE, computed from its daily closing prices.

IndicatorValueReading
50-day simple moving average22.14Price below
10-day exponential moving average11.55Price below
Relative strength index (14-day)25.08Oversold
MACD line (12/26/9)-3.9485Below its signal line
Bollinger bands (20-day, 2σ)5.51 – 27.80Price below the lower band

Analyses

Recent CUE.US analyses are locked — sign in to read them or generate a fresh one.

CaseDescriptionDate

Frequently asked questions

What is the bull case for Cue Biopharma, Inc.?
The recent analyses noted a sharp rebound in price on high volume from a one-day low as a potential upside driver.
What are the risks for Cue Biopharma, Inc.?
Risks discussed included the stock's dramatic price collapse through major technical levels, its significant distance below key moving averages, and a lack of substantive news flow or financial details from recent earnings reports.
Is Cue Biopharma, Inc. bullish or bearish?
Recent AI analyses of Cue Biopharma, Inc. examined factors on both sides. Discussed upside: The recent analyses noted a sharp rebound in price on high volume from a one-day low as a potential upside driver. Discussed risks: Risks discussed included the stock's dramatic price collapse through major technical levels, its significant distance below key moving averages, and a lack of substantive news flow or financial details from recent earnings reports. These are descriptive observations, not a recommendation.
What is the latest sentiment on Cue Biopharma, Inc.?
News flow for Cue Biopharma was sparse, with limited company-specific events and a lack of detailed financial information. Social media discussion was not covered in the provided notes.
How does Market Scanner analyse Cue Biopharma, Inc.?
Every analysis of Cue Biopharma, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Cue Biopharma, Inc.?

The recent analyses noted a sharp rebound in price on high volume from a one-day low as a potential upside driver.

What are the risks for Cue Biopharma, Inc.?

Risks discussed included the stock's dramatic price collapse through major technical levels, its significant distance below key moving averages, and a lack of substantive news flow or financial details from recent earnings reports.

Is Cue Biopharma, Inc. bullish or bearish?

Recent AI analyses of Cue Biopharma, Inc. examined factors on both sides. Discussed upside: The recent analyses noted a sharp rebound in price on high volume from a one-day low as a potential upside driver. Discussed risks: Risks discussed included the stock's dramatic price collapse through major technical levels, its significant distance below key moving averages, and a lack of substantive news flow or financial details from recent earnings reports. These are descriptive observations, not a recommendation.

What is the latest sentiment on Cue Biopharma, Inc.?

News flow for Cue Biopharma was sparse, with limited company-specific events and a lack of detailed financial information. Social media discussion was not covered in the provided notes.

How does Market Scanner analyse Cue Biopharma, Inc.?

Every analysis of Cue Biopharma, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.

Read the methodology

Bundles used
claude-medium-v2

Run a fresh CUE.US analysis

Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.

Or read 1 earlier report



Most analyzed tickers